Combination therapy shows potential as novel treatment for adenoid cystic carcinoma in phase II study

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MD Anderson researchers, led by Renata Ferrarotto, conducted a phase II trial evaluating the combination of the VEGFR inhibitor axitinib plus the PD-L1 inhibitor avelumab in 28 patients with progressive recurrent or metastatic adenoid cystic carcinoma, a rare salivary gland cancer for which there are limited treatment options. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

I write a weekly blog for Georgetown University’s Lombardi Comprehensive Cancer Center community. Here I share an updated version of a blog post I wrote in September 2024, now supplemented by some poems I have written over the years that inspired paintings by my wife Harriet Weiner, who is a much better artist than I am a poet or writer. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login